Other BRAF inhibitors, such as lifirafenib (BGB-283), BGB-3245, and binimetinib (MEK162), have been considered as potential target therapy options for NSCLC with BRAF mutations. This evidence concerns the gene BRAF and non-small cell lung carcinoma.